Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus

Human Pathology

Volumn 29, Issue 2, 1998, Pages 127-130

  Park, Won Sang ^b   Vortmeyer, Alexander O ^b   Pack, Svetlana ^b   Duray, Paul H ^b   Böni, Roland ^b   Guerami, Amir Ali ^b   Emmert Buck, Michael R ^b   Liotta, Lance A ^b   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

Chromosome 17; Chromosome 9; Dysplastic nevus; Loss of heterozygosity; PCR

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME 17P; CHROMOSOME 9P; CHROMOSOME LOSS; CLINICAL ARTICLE; DYSPLASTIC NEVUS; FEMALE; GENE DELETION; HEMIZYGOSITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MELANOMA;

EID: 0031909301     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90221-0     Document Type: Article

References (35)

1. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
2. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
3. Kamb A, Shattuck-Eidens D, Eekes R, et al: Analysis of the p16(CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22-26, 1994
4. Lukas J, Parry D, Aagaard L, et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-506, 1995
5. Nobori T, Miura K, Wu DJ, et al: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
6. Liu Q, Yan Y-X, McClure M, et al: MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophageal squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene 10:619-622, 1995
7. Williamson MP, Elder PA, Shaw ME, et al: p16(CDKN2) is a major target at 9p21 in bladder cancer. Hum Mol Genet 4:1569-1577, 1995
8. Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210-212, 1995
9. Koh J, Enders GH, Dynlacht BD, et al: Tumour-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature 375:506-510, 1995
10. Crawford LC, Pim DC, Gurney EG, et al: Detection of a common feature in several tumor cell lines: A 53,000-dalton protein. Proc Natl Acad Sci U S A 78:41-45, 1981
11. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutation in human cancer. Science 253:49-53, 1991
12. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708, 1989
13. Clark WH Jr, Reimer RR, Greene M, et al: Origin of familial malignant melanomas from heritable melanocytic lesions. Arch Dermatol 114:732-738, 1978
14. Ackerman AB, Mihara I: Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas. HUM PATHOL 16:87-91, 1985
15. Crutcher WA, Sagebiel RW: Prevalence of dysplastic nevi in a community practice. Lancet 1:729, 1984
16. Welkovich B, Schmoeckel C, Landthaler M, et al: Dysplastic nevus syndrome. Arch Dermatol 123:1280, 1987
17. Piepkorn M, Meyer LJ, Goldgar D, et al: The dysplastic nevus: A highly prevalent trait correlating poorly with clinical phenotype. J Cutan Pathol 15:337, 1988 (abstr)
18. Elder DE, Goldman LI, Goldman SC, et al: Dysplastic nevus syndrome: Phenotype association of sporadic cutaneous melanoma. Cancer 46:1787-1794, 1980
19. Swerdlow AJ, English J, MacKie RM, et al: Benign melanocytic naevi as a risk factor for malignant melanoma. Br J Med 292:1555-1559, 1986
20. Nordlund JJ, Kirkwood J, Forget BM, et al: Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 45:1855-1861, 1985
21. Bale SJ, Dracopoli NC, Tucker MA, et al: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic naevus to chromosome 1p. N Engl J Med 320:1367-1372, 1989
22. Cowan JM, Halaban R, Francke U: Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 80:1159-1164, 1988
23. Elder DE, Murphy GF: Melanocytic tumor of the skin, in Rosai J, Sobin LH (eds): Atlas of Tumor Pathology. AFIP fascicle 2. Series 3. Washington, DC, AFIP, 1995, pp 90-95
24. Barnhill RL, Hurwitz S, Duray PH, et al: The dysplastic nevus: Recognition and management. Plast Reconstr Surg 81:280-289, 1988
25. Diaz MO, Ziemin S, Le Beau MM, et al: Homozygous deletion of the a- and β1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 85:5259-5263, 1988
26. Diaz MO, Rubin CM, Harden A, et al: Deletions of Interferon genes in acute lymphoblastic leukemia. N Engl J Med 322:77-82, 1990
27. Merlo A, Gabrielson E, Askin F, et al: Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 54:640-642, 1994
28. Lassam NJ, From L, Kahn HJ: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53:2235-2238, 1993
29. Christofolini M, Sebastiana B, Girlando S, et al: p53 protein expression in nevi and melanomas. Arch Dermatol 129:739-743, 1993
30. Clark WH, Elder DE, Guerry D, et al: A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. HUM PATHOL 15:1147-1165, 1984
31. National Institutes of Health Consensus Development Conference Summary: Precursors to malignant melanoma J Am Acad Dermatol 10:683-688, 1984
32. Rhodes AR, Harrist TJ, Day CL, et al: Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 9:563-574, 1983
33. Black WC: Residual dysplastic and other nevi in superficial spreading melanoma. Cancer 62:163-173, 1988
34. Healy E, Belgaid CE, Takata M: Allele types of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 56:589-593, 1996
35. Zhuang Z, Bertheau P, Emmert-Buck MR, et al: A microdissection technique for archival DNA analysis of specific cell populations in lesion <1 mm in size. Am J Pathol 146:620-625, 1995